FR3025722A1 - ANTIOXIDIZING FOOD COMPOSITION IN THE FORM OF GEL - Google Patents
ANTIOXIDIZING FOOD COMPOSITION IN THE FORM OF GEL Download PDFInfo
- Publication number
- FR3025722A1 FR3025722A1 FR1402031A FR1402031A FR3025722A1 FR 3025722 A1 FR3025722 A1 FR 3025722A1 FR 1402031 A FR1402031 A FR 1402031A FR 1402031 A FR1402031 A FR 1402031A FR 3025722 A1 FR3025722 A1 FR 3025722A1
- Authority
- FR
- France
- Prior art keywords
- extract
- composition
- content
- composition according
- pomegranate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 235000013305 food Nutrition 0.000 title description 3
- 230000003064 anti-oxidating effect Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 35
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 240000002234 Allium sativum Species 0.000 claims abstract description 17
- 235000004611 garlic Nutrition 0.000 claims abstract description 17
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 14
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 14
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 13
- 235000013976 turmeric Nutrition 0.000 claims abstract description 13
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims abstract description 11
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims abstract description 11
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 11
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims abstract description 10
- 229940109529 pomegranate extract Drugs 0.000 claims abstract description 8
- 241000219784 Sophora Species 0.000 claims abstract description 7
- 239000003349 gelling agent Substances 0.000 claims abstract description 7
- 229940094952 green tea extract Drugs 0.000 claims abstract description 6
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 6
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 6
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 6
- 230000004792 oxidative damage Effects 0.000 claims abstract description 3
- 230000007170 pathology Effects 0.000 claims abstract description 3
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000011669 selenium Substances 0.000 claims description 11
- 229910052711 selenium Inorganic materials 0.000 claims description 10
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 9
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 6
- 244000215068 Acacia senegal Species 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- 229930003761 Vitamin B9 Natural products 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 235000019159 vitamin B9 Nutrition 0.000 claims description 4
- 239000011727 vitamin B9 Substances 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical group OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 3
- 235000013525 pomegranate juice Nutrition 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims 2
- 150000003342 selenium Chemical class 0.000 claims 1
- 244000269722 Thea sinensis Species 0.000 description 16
- 230000003078 antioxidant effect Effects 0.000 description 11
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 235000009569 green tea Nutrition 0.000 description 7
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 244000294611 Punica granatum Species 0.000 description 4
- 235000014360 Punica granatum Nutrition 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 235000006468 Thea sinensis Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 244000223014 Syzygium aromaticum Species 0.000 description 3
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XUHLIQGRKRUKPH-GCXOYZPQSA-N Alliin Natural products N[C@H](C[S@@](=O)CC=C)C(O)=O XUHLIQGRKRUKPH-GCXOYZPQSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- XUHLIQGRKRUKPH-UHFFFAOYSA-N S-allyl-L-cysteine sulfoxide Natural products OC(=O)C(N)CS(=O)CC=C XUHLIQGRKRUKPH-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- XUHLIQGRKRUKPH-DYEAUMGKSA-N alliin Chemical class OC(=O)[C@@H](N)C[S@@](=O)CC=C XUHLIQGRKRUKPH-DYEAUMGKSA-N 0.000 description 2
- 235000015295 alliin Nutrition 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 150000002206 flavan-3-ols Chemical class 0.000 description 2
- 235000011987 flavanols Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 235000012055 fruits and vegetables Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 108010092760 Alliin lyase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000011303 Brassica alboglabra Nutrition 0.000 description 1
- 235000011302 Brassica oleracea Nutrition 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 244000308180 Brassica oleracea var. italica Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000219991 Lythraceae Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 102000008114 Selenoproteins Human genes 0.000 description 1
- 108010074686 Selenoproteins Proteins 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007172 age related pathology Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002012 ayurvedic medicine Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- 229960005559 sulforaphane Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/231—Pectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une composition sous forme de gel comprenant au moins un extrait de rhizome de curcuma, un extrait de fleurs de Sophora du Japon, un extrait de grenade, un extrait de thé vert, un extrait de bulbe d'ail, un extrait de brocoli, de la vitamine B6, et un agent gélifiant ; une dosette comprenant une telle composition sous forme de gel et l'utilisation d'une telle composition pour la prévention de pathologies associées à des dommages oxydatifs dus aux radicaux libres tels que les cancers.The present invention relates to a gel composition comprising at least one extract of turmeric rhizome, an extract of Sophora flowers from Japan, a pomegranate extract, a green tea extract, a garlic bulb extract, an extract broccoli, vitamin B6, and a gelling agent; a pod comprising such a composition in gel form and the use of such a composition for the prevention of pathologies associated with oxidative damage due to free radicals such as cancers.
Description
1 Domaine de L'invention La présente invention concerne le domaine de la prévention du cancer et, plus spécifiquement, une composition sous forme de gel spécifique et destinée à une prise orale.FIELD OF THE INVENTION The present invention relates to the field of cancer prevention and, more specifically, to a composition in the form of a specific gel and intended for oral intake.
Art antérieur de l'invention Le cancer est une maladie caractérisée par une prolifération cellulaire (tumeur) anormalement importante au sein d'un tissu normal de l'organisme, de telle manière que la survie de ce dernier en vient à être menacée. Les cellules de cette tumeur dérivent en général toutes d'un même clone ; lequel clone est assimilable à la cellule initiatrice de cancer qui a acquis certaines caractéristiques lui permettant de se diviser indéfiniment. En fonction de l'évolution de la maladie, certaines cellules tumorales sont susceptibles de migrer dans l'organisme et de former ainsi ce que l'on appelle des métastases. Le terme « Cancer » est un terme général qui désigne une maladie pour lesquelles certaines cellules d'un organisme adoptent un comportement anormal caractérisé par : - une capacité proliférative qui n'est plus limitée (croissance à l'infini) ; - la disparition du phénomène d'apoptose (mort cellulaire); - et l'acquisition d'un pouvoir invasif et de production de métastases. Les cellules associées à un cancer sont qualifiées de « cancéreuses » ou « tumorales » et elles peuvent former une tumeur maligne (un néoplasme) ou se propager à travers le corps. Les facteurs de risques au cancer sont multiples et peuvent être internes (familial, mutation spontanée, etc.), et/ou externes (alimentation, exposition à des agents infectieux ou à des substances cancérigènes ou à des conditions telles que l'irradiation, etc.).BACKGROUND OF THE INVENTION Cancer is a disease characterized by an abnormally large cell proliferation (tumor) within a normal body tissue, so that the survival of the latter comes to be endangered. The cells of this tumor generally derive from the same clone; which clone is comparable to the cancer initiating cell which has acquired certain characteristics allowing it to divide indefinitely. Depending on the evolution of the disease, some tumor cells are likely to migrate into the body and thus form what is called metastases. The term "Cancer" is a general term for a disease for which certain cells of an organism adopt an abnormal behavior characterized by: - a proliferative capacity which is no longer limited (growth to infinity); - the disappearance of the phenomenon of apoptosis (cell death); - and the acquisition of an invasive power and metastasis production. Cells associated with cancer are referred to as "cancerous" or "tumoral" and can form a malignant tumor (a neoplasm) or spread through the body. The risk factors for cancer are multiple and can be internal (familial, spontaneous mutation, etc.), and / or external (diet, exposure to infectious agents or carcinogens or conditions such as irradiation, etc. .).
Si l'impact des facteurs internes n'est pas négligeable, avec notamment des facteurs hormonaux ou épigénétiques ; des études scientifiques n'associent que 5 à 10 % des cas de cancer à des facteurs génétiques contre 25 à 30 % au tabagisme, 30 à 35 % aux régimes alimentaires (dont l'alcool), 15 à 20 % aux infections, et 10 à 25 % aux 3025722 2 autres facteurs (rayons ionisants, stress, activités physique, pollution de l'environnement). Durant la dernière décennie, plusieurs types de cancers semblent en augmentation, si dans certains cas cette progression est facilement liée à des facteurs de risque 5 identifiés (tabac, alcool, polluants industriels reconnus cancérigènes, obésité, sédentarité, exposition au soleil) dans certains cas il est difficile d'attribuer à des facteurs précis l'augmentation observée. L'amélioration des outils de diagnostic et le vieillissement de la population expliquent une part importante de la progression de l'incidence de certains cancers. À l'inverse une étude de l'Institut de veille sanitaire 10 montre que les cancers de l'estomac, de l'oesophage (chez l'homme), du col de l'utérus et le lymphome hodgkinien ont régressé entre 1980 et 2000. La double prise de conscience actuelle de cette forte incidence du cancer associée à notre mode de vie moderne ont amené à une réflexion visant à adapter notre mode de vie en vue de mieux se prémunir contre cette maladie.If the impact of internal factors is not negligible, especially with hormonal or epigenetic factors; scientific studies associate only 5 to 10% of cancer cases with genetic factors, 25 to 30% for smoking, 30 to 35% for diets (including alcohol), 15 to 20% for infections, and 10 to 25% to 3025722 2 other factors (ionizing radiation, stress, physical activity, environmental pollution). During the last decade, several types of cancers appear to be increasing, although in some cases this progression is easily linked to identified risk factors (tobacco, alcohol, recognized carcinogenic industrial pollutants, obesity, sedentary lifestyle, sun exposure) in certain cases. it is difficult to attribute the observed increase to specific factors. The improvement of diagnostic tools and the aging of the population explain a large part of the increase in the incidence of certain cancers. Conversely, a study by the French Institute for Public Health Surveillance 10 shows that cancers of the stomach, esophagus (in humans), cervical cancer and Hodgkin's lymphoma decreased between 1980 and 2000 The current dual awareness of this high incidence of cancer associated with our modern lifestyle has led to a reflection to adapt our lifestyle to better guard against this disease.
15 Ces dernières années, il est apparu que le cancer, ou tout du moins certains cancers, touchait avec une moindre incidence certaines sous-populations. Si cette moindre sensibilité a pu parfois s'expliquer par des causes internes (génétiques), des causes externes et notamment alimentaires l'ont parfois expliquées. Il est ainsi apparu que la consommation de fruits et légumes exerce un effet 20 protecteur probable sur les cancers des voies aérodigestives supérieures (oesophage, cavité buccale, larynx et pharynx), les cancers de l'estomac et du poumon (pour les fruits seulement). A noter en outre que, les fruits et légumes, faibles en calories, participent au maintien d'un poids corporel normal et à la prévention du surpoids et de l'obésité.15 In recent years, it has emerged that cancer, or at least some cancers, has a lower incidence of certain sub-populations. Although this lesser sensitivity could sometimes be explained by internal (genetic) causes, external and especially food causes have sometimes explained it. It has thus been found that fruit and vegetable consumption has a probable protective effect on cancers of the upper aerodigestive tract (esophagus, oral cavity, larynx and pharynx), cancers of the stomach and lung (for fruits only). . It should also be noted that fruits and vegetables, which are low in calories, contribute to the maintenance of normal body weight and the prevention of overweight and obesity.
25 En outre, il est apparu qu'une alimentation riche en fibres (céréales complètes, fruits, légumes, légumineuses) étaient associée à un moindre risque de développer un cancer colorectal (niveau de preuve probable). Au-delà de ces généralités, certains composants ont pu être associés à des actions anticancéreuses comme le curcuma (du fait de la curcumine).In addition, it was found that a diet high in fiber (whole grains, fruits, vegetables, legumes) was associated with a lower risk of developing colorectal cancer (probable level of evidence). Beyond these generalities, certain components could be associated with anticancer actions such as turmeric (because of curcumin).
3025722 3 Partant de ces résultats différents compléments alimentaires à vocation préventive à l'encontre du cancer ont été développés, soit sous forme de poudre, soit sous forme de gélules. Descriptif de l'invention 5 Les inventeurs ont maintenant mis au point une composition sous forme de gel, laquelle comprend au moins : un extrait de rhizome de curcuma ; un extrait de fleurs de Sophora du Japon ; - un extrait de grenade ; 10 un extrait de thé vert ; un extrait de bulbe d'ail ; un extrait de brocoli ; - de la vitamine B6 ; et - un agent gélifiant.On the basis of these results, various dietary supplements with a preventive function against cancer have been developed, either in the form of a powder or in the form of capsules. Description of the invention The inventors have now developed a composition in the form of a gel, which comprises at least: an extract of turmeric rhizome; an extract of Sophora flowers from Japan; - a pomegranate extract; 10 green tea extract; an extract of garlic bulb; broccoli extract; - vitamin B6; and a gelling agent.
15 Les inventeurs ont pu mettre en évidence qu'une telle composition alimentaire, destinée à une prise orale, malgré sa teneur en antioxydants très élevée pouvait se trouver sous forme de gel. L'avantage d'une telle forme étant qu'elle a montré une perturbation nettement moindre du transit chez ses utilisateurs qu'une composition sous forme de poudre.The inventors have been able to demonstrate that such a food composition, intended for oral intake, despite its very high antioxidant content could be in the form of a gel. The advantage of such a form is that it has shown a significantly lower disturbance of transit in its users than a composition in powder form.
20 De surcroît, les utilisateurs l'ont consommé bien plus facilement qu'une composition sous forme de gélule, associée plus fortement à une forme « médicale » et donc à la maladie. Finalement, les utilisateurs ont appréciés les qualités organoleptiques de la composition selon l'invention, ce qui a grandement facilité sa prise quotidienne, 25 laquelle prise quotidienne est bien évidemment nécessaire pour produire ses effets préventifs avec le temps. Pour ce qui est des composants de celle-ci, on trouve tout d'abord le curcuma (Curcuma longa) est une plante herbacée rhizomateuse vivace du genre Curcuma de la famille des Zingibéracées originaire du sud de l'Asie. Il est connu en Occident depuis 30 l'Antiquité et décrit par Dioscoride dans ses Materia Medica.In addition, users have consumed it much more easily than a capsule composition, associated more strongly with a "medical" form and therefore with the disease. Finally, the users have appreciated the organoleptic qualities of the composition according to the invention, which has greatly facilitated its daily intake, which daily intake is obviously necessary to produce its preventive effects over time. In terms of its components, turmeric (Curcuma longa) is a rhizomatous perennial herb of the genus Turmeric of the family Zingiberaceae native to southern Asia. He is known in the West since 30 Antiquity and described by Dioscorides in his Materia Medica.
3025722 4 Le curcuma est reconnu en Occident pour ses propriétés antioxydantes par lesquelles il aide l'organisme à lutter contre le stress et à maintenir l'efficacité des défenses naturelles. Il est également utilisé depuis très longtemps comme anti-inflammatoire par la médecine ayurvédique indienne et c'est probablement l'anti- 5 inflammatoire naturel le plus puissant identifié à ce jour. Maintenant, il a été mis en évidence qu'il peut jouer aussi un rôle dans la prévention du cancer et à âge égal, les Indiens ont huit fois moins de cancers du poumon que les Occidentaux, neuf fois moins de cancers du côlon, 5 fois moins de cancers du sein et jusqu'à dix fois moins de cancers du rein. Un des éléments pouvant expliquer 10 cette différence pourrait être attribuable à leur consommation élevée de curcuma, laquelle est en moyenne de 1,5 à 2 g de curcuma par jour (l'équivalent d'un quart à une demi-cuillère à café). Le principe actif du curcuma, la curcumine, est ainsi l'objet de recherches actives. Cette molécule se montre capable d'inhibe in vitro la croissance d'un très grand nombre 15 de cancers : côlon, foie, estomac, ovaires, sein, leucémie entre autres. L'extrait utilisé de curcuma correspond au rhizome de ce dernier qui comprend de 0,5 à 3% en poids de curcominoïdes répartis entre la curcumine (0,4 à 2,2%), la déméthoxycurcumine (0,1 à 1%). Avantageusement, la teneur de la composition selon l'invention en extrait de 20 rhizome de curcuma est comprise entre 1 et 3%, de préférence entre 1,5 et 2%. Le Sophora du Japon, ou Styphnolobium japonicum, est une espèce d'arbre de la famille des Fabaceae. La fleur de ce dernier présente la particularité de comprendre des flavonoïdes en quantité, lesquels consistent principalement en la quercétine, la rutine, l'isorhamnétine 25 et le kaempférol. Un des premiers bienfaits de ces molécules consistent en leur activité antioxydante, à même de neutraliser les radicaux libres responsables pour partie du vieillissement et de l'altération de l'organisme. La fleur de Sophora du Japon présente l'avantage de renfermer jusqu'à 15 à 20% de rutine. Avantageusement, la teneur de la composition selon l'invention en extrait de fleur 30 de Sophora du Japon est comprise entre 1 et 3%, de préférence entre 1,5 et 2%.3025722 4 Turmeric is recognized in the West for its antioxidant properties by which it helps the body to fight against stress and maintain the effectiveness of natural defenses. It has also been used for a very long time as an anti-inflammatory by Indian Ayurvedic medicine and is probably the strongest natural anti-inflammatory identified to date. Now, it has been shown that it can also play a role in cancer prevention and at the same age, Indians have eight times less lung cancer than Westerners, nine times less colon cancer, 5 times fewer breast cancers and up to ten times fewer kidney cancers. One of the factors that may explain this difference could be attributable to their high consumption of turmeric, which averages 1.5 to 2 g of turmeric per day (the equivalent of a quarter to a half teaspoon). The active ingredient of turmeric, curcumin, is thus the subject of active research. This molecule is capable of inhibiting in vitro the growth of a very large number of cancers: colon, liver, stomach, ovaries, breast, leukemia among others. The extract used turmeric corresponds to the rhizome of the latter which comprises from 0.5 to 3% by weight of curcominoids distributed between curcumin (0.4 to 2.2%), demethoxycurcumin (0.1 to 1%) . Advantageously, the content of the composition according to the invention in turmeric rhizome extract is between 1 and 3%, preferably between 1.5 and 2%. The Japanese Sophora, or Styphnolobium japonicum, is a tree species of the family Fabaceae. The flower of the latter has the particularity of comprising flavonoids in quantity, which consist mainly of quercetin, rutin, isorhamnetin and kaempferol. One of the first benefits of these molecules is their antioxidant activity, able to neutralize free radicals responsible for part of the aging and alteration of the body. The Sophora flower from Japan has the advantage of containing up to 15 to 20% rutin. Advantageously, the content of the composition according to the invention in Sophora flower extract from Japan is between 1 and 3%, preferably between 1.5 and 2%.
3025722 5 La grenade, quant à elle, est le fruit du grenadier, ou Punica granatum, qui appartient à la famille des Lythracées et que l'on trouve sur un large domaine géographique qui s'étend de l'Asie occidentale à l'Asie centrale. Cette dernière est ainsi une bonne source de fibres alimentaires, de folate, et également une très bonne source 5 de vitamine C. L'arille de la grenade contient en outre des flavanols (ou catéchines) et des dimères de flavanols (des procyanidols), de même qu'un grand nombre de polyphénols particulièrement efficaces et auxquels on peut vraisemblablement attribuer ses effets bénéfiques pour la santé. Tous ces composants contribuent à doter le jus de grenade de propriétés 10 antioxydantes des plus intéressantes. Avantageusement, la teneur de la composition selon l'invention en extrait de grenade est comprise entre 2 et 10%, de préférence entre 3 et 7%, voir entre 4 et 6%. Maintenant, et pour ce qui est de cet extrait de grenade, on préfèrera utiliser le jus de grenade.The pomegranate is the fruit of the pomegranate tree, Punica granatum, which belongs to the family Lythraceae and found in a wide geographical area stretching from Western Asia to Asia. Central. The latter is thus a good source of dietary fiber, folate, and also a very good source of vitamin C. The pomegranate aril also contains flavanols (or catechins) and dimers of flavanols (procyanidols), as well as a large number of particularly effective polyphenols, whose health benefits are likely to be attributed. All of these components contribute to providing the pomegranate juice with the most interesting antioxidant properties. Advantageously, the content of the composition according to the invention in pomegranate extract is between 2 and 10%, preferably between 3 and 7%, or between 4 and 6%. Now, and for this pomegranate extract, we would prefer to use pomegranate juice.
15 Le théier (Camellia sinensis), appelé aussi thé, comme l'infusion de ses feuilles, est une espèce d'arbustes de la famille des Théacées. Il est originaire d'Extrême-Orient et est largement cultivé pour ses feuilles qui, une fois séchées et plus ou moins oxydées, servent à la préparation par infusion de cette boisson incontournable. Le thé vert correspond à une variété particulière de thé liée à la préparation des 20 feuilles de thé une fois récoltées. Le thé vert est en fait un thé très peu oxydé lors de sa fabrication, laquelle permet de conserver ainsi intactes ses propriétés. Les propriétés du thé vert sont multiples : riche en tanins, ce sont ces polyphénols antioxydants qui donnent au thé son arôme et son goût amer particulier. Le thé vert contient également de la vitamine C. Mais ce qui démarque le thé vert des autres, c'est 25 qu'il contient une catéchine nommée épigallocatéchine EPGC ou encore épigallocatéchine-3-gallate (EGCG). L'EPGC possède des propriétés bien plus puissantes que celles d'un simple antioxydant. Le thé vert (vert car non fermenté) contient ainsi dix fois plus d'EPGC que le thé noir et 2,5 fois plus que le thé Oolong. Quant au taux de caféine (théine), il est semblable à celui du thé noir soit 20-90 mg par tasse mais ses effets excitants sont atténués par la présence des tanins. Le thé contient 3025722 6 également de la théanine, un acide aminé analogue au glutamate, qui a un effet apaisant qui inhibe l'effet hypertenseur de la caféine. Là encore, tous ces composants contribuent à doter le thé vert de propriétés antioxydantes puissantes et adaptées à prévenir les dommages des stress oxydatifs.The tea tree (Camellia sinensis), also called tea, as the infusion of its leaves, is a species of shrubs of the family of Theaeae. It is native to the Far East and is widely grown for its leaves which, once dried and more or less oxidized, are used for the preparation by infusion of this essential drink. Green tea is a particular variety of tea related to the preparation of tea leaves once harvested. Green tea is actually a tea with very little oxidization during its manufacture, which allows to keep intact its properties. The properties of green tea are multiple: rich in tannins, it is these antioxidant polyphenols that give tea its aroma and bitter taste. Green tea also contains vitamin C. What distinguishes green tea from others is that it contains a catechin called epigallocatechin EPGC or epigallocatechin-3-gallate (EGCG). EPGC has properties far more powerful than those of a simple antioxidant. Green tea (green because unfermented) contains ten times more EPGC than black tea and 2.5 times more than Oolong tea. As for the caffeine (theine), it is similar to that of black tea is 20-90 mg per cup but its exciting effects are mitigated by the presence of tannins. The tea also contains theanine, a glutamate-like amino acid, which has a soothing effect that inhibits the coughing effect of caffeine. Here again, all these components contribute to providing green tea with powerful antioxidant properties that are suitable for preventing damage from oxidative stress.
5 Avantageusement, la teneur de la composition selon l'invention en extrait de grenade est comprise entre 1 et 5%, de préférence entre 2 et 4%, voir entre 2,5 et 3%. Maintenant, et pour ce qui est de cet extrait de thé vert, on préfèrera utiliser un extrait liquide de thé vert, de préférence un extrait de thé vert concentré lequel comprendra de 15 à 45% de matière sèche, de préférence de 25 à 35% de matière sèche.Advantageously, the content of the composition according to the invention in pomegranate extract is between 1 and 5%, preferably between 2 and 4%, or between 2.5 and 3%. Now, and with regard to this green tea extract, it will be preferable to use a liquid green tea extract, preferably a concentrated green tea extract which will comprise from 15 to 45% of dry matter, preferably from 25 to 35% by weight. dry matter.
10 Pour l'ail, celui qui est cultivé (Allium sativum) est une plante potagère vivace monocotylédone dont les bulbes, à l'odeur et au goût fort, sont souvent employés comme condiment en cuisine. Une tête d'ail se compose de plusieurs caïeux ou gousses d'ail. Différentes études établissent que la consommation régulière d'une gousse d'ail (3 g) par jour réduirait de moitié le risque de cancer de l'estomac, du colon et du rectum.For garlic, the one grown (Allium sativum) is a monocotyledonous perennial vegetable whose bulbs, with a strong smell and taste, are often used as a condiment in the kitchen. A head of garlic consists of several cloves or cloves of garlic. Various studies have shown that regular consumption of one clove of garlic (3 g) per day would reduce the risk of cancer of the stomach, colon and rectum by half.
15 Cette action résulterait notamment de l'alliine, qui est un sulfoxyde et qui constitue un dérivé de la cystéine. Lorsque de l'ail frais est écrasé ou haché, cet alliine est convertit par l'enzyme alliinase en allicine qui est responsable de l'arôme de l'ail frais. En outre, du fait de sa composition en alliine (près de 0,5 à 1,3% dans le bulbe) qui a des propriétés de captage du radical hydroxyle, l'ail s'est révélée avoir des 20 propriétés antioxydantes très intéressantes. Maintenant, celles-ci sont également associées pour partie aux flavonoïdes et au tocophérol que le bulbe d'ail renferme en quantités. Avantageusement, la teneur de la composition selon l'invention en extrait de bulbe d'ail est comprise entre 0,01 et 0,5%, de préférence entre 0,01 et 0,05%.This action would result in particular from the alliine, which is a sulfoxide and which is a derivative of cysteine. When fresh garlic is crushed or chopped, this alliin is converted by the alliinase enzyme into allicin which is responsible for the aroma of fresh garlic. In addition, because of its alliin composition (about 0.5 to 1.3% in the bulb) which has hydroxyl radical uptake properties, garlic has been found to have very interesting antioxidant properties. Now, these are also associated in part with flavonoids and tocopherol that the bulb of garlic contains in quantities. Advantageously, the content of the composition according to the invention in garlic bulb extract is between 0.01 and 0.5%, preferably between 0.01 and 0.05%.
25 Maintenant, et pour ce qui est de cet extrait de bulbe d'ail, on préfèrera utiliser un extrait sec, avantageusement désodorisé. En lien avec le brocoli (Brassica oleracea var. italica), il s'agit d'une variété de chou qui est originaire du sud de l'Italie. Le brocoli présente une tige centrale ferme ramifiée en petits bouquets qui, à la floraison, sont parsemés de minuscules fleurs 30 jaunes. Habituellement de couleur vert foncé à vert sauge, le brocoli peut aussi être blanc ou pourpre (violacé).Now, with respect to this garlic bulb extract, it will be preferred to use a dry extract, advantageously deodorized. In connection with broccoli (Brassica oleracea var., Italica), it is a variety of cabbage that is native to southern Italy. Broccoli has a firm central stem branched into small bunches which, at bloom, are dotted with tiny yellow flowers. Usually dark green to sage green, broccoli can also be white or purple (purplish).
3025722 7 Pour ce qui est de ses propriétés, il bénéficie d'une action préventive du cancer (et principalement le cancer du côlon) grâce aux fibres et aux composés soufrés et d'autres antioxydants : indoles, sulforaphane, glutathion, quercétine, [3-carotène, brocoline (alcaloïde typique du brocoli) : ces substances ont la propriété de neutraliser certains 5 composés toxiques présents dans l'organisme (radicaux libres). Avantageusement, la teneur de la composition selon l'invention en extrait de brocoli est comprise entre 1 et 5%, de préférence entre 2 et 4%, voir entre 2,5 et 3%. Maintenant, et pour ce qui est de cet extrait de brocoli, on préférera utiliser un extrait sec, et surtout un extrait atomisé. Typiquement, cet extrait atomisé comprend des 10 particules présentant un diamètre inférieur à 1 p,m. La vitamine B6, elle, intervient dans le métabolisme de l'homocystéine dont la carence entraine une baisse importante de la tonicité. En lien avec le système nerveux, la vitamine B6 participe également à la biosynthèse de la sérotonine et son apport journalier recommandé (AJR) est de 1,4 mg selon la directive 2008/100/CE.In terms of its properties, it benefits from a preventive action against cancer (and mainly colon cancer) thanks to fibers and sulfur compounds and other antioxidants: indoles, sulforaphane, glutathione, quercetin, [3]. -carotene, brocoline (alkaloid typical of broccoli): these substances have the property of neutralizing certain toxic compounds present in the body (free radicals). Advantageously, the content of the composition according to the invention in broccoli extract is between 1 and 5%, preferably between 2 and 4%, or between 2.5 and 3%. Now, and as for this broccoli extract, it will be preferred to use a dry extract, and especially an atomized extract. Typically, this atomized extract comprises particles having a diameter of less than 1 μm. Vitamin B6, it is involved in the metabolism of homocysteine whose deficiency causes a significant decline in tone. In connection with the nervous system, vitamin B6 also participates in the biosynthesis of serotonin and its recommended daily intake (RDA) is 1.4 mg according to the directive 2008/100 / CE.
15 De préférence, la composition selon l'invention présente une teneur en vitamine B6 est comprise entre 0,01 et 0,05%, de préférence entre 0,01 et 0,03%. Cette proportion est adaptée de sorte que la prise de la composition selon l'invention se rapproche de l'AJR sans risquer de (trop) l'excéder. Par agent gélifiant, on entend un agent qui permette de donner à la composition 20 selon l'invention la consistance d'un gel. De tels agents sont bien connus de l'homme du métier et comprennent notamment la gomme arabique (ou gomme d'acacia), la gomme xanthane, la gélatine, la pectine, les alginates, les carraghénanes, ou encore l'agar-agar. La combinaison de gomme arabique et de gomme xanthane a montré, en lien avec 25 la composition selon l'invention, une grande facilité de prise pour l'utilisateur et une assimilation rapide. La teneur en agent gélifiant de la composition selon l'invention est dépendante de l'agent gélifiant utilisé et peut être simplement adaptée par l'homme du métier. Elle est typiquement supérieure à 0,1% voir 0,5% et inférieure à 10% voir 5%.Preferably, the composition according to the invention has a vitamin B 6 content of between 0.01 and 0.05%, preferably between 0.01 and 0.03%. This proportion is adapted so that the setting of the composition according to the invention is close to the AJR without risking (too) exceed it. By gelling agent is meant an agent which makes it possible to give the composition 20 according to the invention the consistency of a gel. Such agents are well known to those skilled in the art and include gum arabic (or gum acacia), xanthan gum, gelatin, pectin, alginates, carrageenans, or agar agar. The combination of gum arabic and xanthan gum has shown, in connection with the composition according to the invention, a great ease of grip for the user and rapid assimilation. The content of gelling agent of the composition according to the invention is dependent on the gelling agent used and can be simply adapted by those skilled in the art. It is typically greater than 0.1% or 0.5% and less than 10% or 5%.
3025722 8 La composition selon l'invention pourra en outre comprendre différents constituants bénéficiant de propriétés antioxydantes ou stimulatrices. On ajoutera ainsi de préférence à cette dernière du sélénium, qui appartient à la famille des chalcogènes, de symbole Se et de numéro atomique 34.The composition according to the invention may further comprise different constituents having antioxidant or stimulating properties. Thus selenium, which belongs to the family of chalcogenes, of symbol Se and atomic number 34 is preferably added to the latter.
5 Le sélénium est un oligo-élément constituant des sélénoprotéines dont fait partie le principal antioxydant intracellulaire, la glutathion peroxydase. On en trouve dans les rognons de porc ou de boeuf, l'ail, le poisson et les mollusques. La nutrition occidentale satisfait largement les besoins quotidiens en cet élément mais il est impossible de prédire les concentrations corporelles de sélénium à partir de l'apport nutritionnel parce 10 que son utilisation et sa rétention sont dépendantes de la présence d'acide folique, de vitamine B12 et négativement affectées par la présence d'homocystéine. Le sélénium utilisé se trouvera sous la forme d'un extrait de levure (ex. Saccharomyces cerevisiae) enrichi en sélénium. Cet enrichissement correspond à une concentration de l'ordre de 1 500 à 3 000ptg de sélénium par gramme d'extrait.Selenium is a micronutrient constituting selenoproteins of which the main intracellular antioxidant, glutathione peroxidase, is one. It is found in pork or beef kidneys, garlic, fish and molluscs. Western nutrition largely meets the daily requirements in this element, but it is impossible to predict selenium body levels from nutritional intake because its use and retention are dependent on the presence of folic acid, vitamin B12 and negatively affected by the presence of homocysteine. The selenium used will be in the form of a yeast extract (eg Saccharomyces cerevisiae) enriched in selenium. This enrichment corresponds to a concentration of the order of 1500 to 3000% of selenium per gram of extract.
15 Il est à noter que le sélénium présent dans cet extrait se trouve sous la forme de séléniométhionine et se présente sous la forme d'un extrait sec. Avantageusement, la teneur de la composition selon l'invention présente une teneur en extrait de levure enrichi en sélénium comprise entre est comprise entre 0,1 et 0,5%, de préférence entre 0,1 et 0,3%.It should be noted that the selenium present in this extract is in the form of seleniomethionine and is in the form of a dry extract. Advantageously, the content of the composition according to the invention has a content of yeast extract enriched with selenium between between 0.1 and 0.5%, preferably between 0.1 and 0.3%.
20 La composition selon l'invention comprendra en outre de préférence de la vitamine B9 qui est essentiel pour limiter le déclin cognitif et palier à l'apparition de pathologies liées à l'âge comme la maladie d'Alzheimer. L'apport journalier recommandé (AJR) en vitamine B9 est de 200 pg selon la directive 2008/100/CE. De préférence, la composition selon l'invention présente une teneur en vitamine 25 B9 comprise entre est comprise entre 0,001 et 0,005%, de préférence entre 0,001 et 0,003%. Cette proportion est adaptée de sorte que la prise de la composition selon l'invention se rapproche de l'AJR sans risquer de (trop) l'excéder. La composition selon l'invention pourra comprendre en outre des acidifiants, parmi lesquels l'acide citrique.The composition of the invention will additionally preferably comprise vitamin B9 which is essential for limiting cognitive decline and for the onset of age-related pathologies such as Alzheimer's disease. The recommended daily intake (RDA) of vitamin B9 is 200 pg according to Directive 2008/100 / EC. Preferably, the composition according to the invention has a vitamin B9 content between 0.001 and 0.005%, preferably between 0.001 and 0.003%. This proportion is adapted so that the setting of the composition according to the invention is close to the AJR without risking (too) exceed it. The composition according to the invention may furthermore comprise acidifiers, among which citric acid.
3025722 9 La teneur en acidifiant de la composition selon l'invention pourra atteindre les 2%, mais sera préférentiellement inférieure ou égale à 1%. De même, la composition selon l'invention pourra comprendre au moins un édulcorant. A titre d'exemple de tels édulcorants, on pourra citer, entre autres, le 5 sucralose, l'extrait de stévia, le xylitol, l'aspartame, le sirop de glucose, le sirop de fructo-oligosaccharide, le maltitol en poudre ou en sirop, l'acésulfame de potassium, le fructooligosaccharide et le cyclamate de sodium. La composition selon l'invention comprendra en outre au moins un conservateur. A titre d'exemples de conservateurs, on pourra citer le sorbate de potassium, le benzoate 10 de sodium ou le palmitate d'ascorbyle (antioxydant). Enfin, la composition selon l'invention pourra comprendre un agent texturant tel que la glycérine. Un second objet de l'invention porte sur une dosette contenant la composition sous forme de gel selon l'invention.The acid content of the composition according to the invention may reach 2%, but will preferably be less than or equal to 1%. Similarly, the composition according to the invention may comprise at least one sweetener. Examples of such sweeteners include, among others, sucralose, stevia extract, xylitol, aspartame, glucose syrup, fructo-oligosaccharide syrup, maltitol powder or syrup, acesulfame potassium, fructooligosaccharide and sodium cyclamate. The composition according to the invention will also comprise at least one preservative. Examples of preservatives that may be mentioned are potassium sorbate, sodium benzoate or ascorbyl palmitate (antioxidant). Finally, the composition according to the invention may comprise a texturing agent such as glycerine. A second subject of the invention relates to a pod containing the composition in gel form according to the invention.
15 L'utilisateur pourra ainsi consommer simplement la dose requise et, s'il le souhaite, l'associer ou la dissoudre dans un verre d'eau. Un troisième objet selon l'invention correspond à l'utilisation d'une composition telle que décrite précédemment pour la prévention de pathologies associées à des dommages oxydatifs dus aux radicaux libres, tels que les cancers, chez un sujet.The user can thus simply consume the required dose and, if he wishes, associate or dissolve it in a glass of water. A third object according to the invention corresponds to the use of a composition as described above for the prevention of pathologies associated with oxidative damage due to free radicals, such as cancers, in a subject.
20 Par cancer, on entend de préférence un cancer oral ou un cancer de l'appareil digestif Les exemples ci-après sont fournis pour illustrer l'invention et ne doivent en aucun cas être considérés comme une limite à la portée de l'invention.By cancer is preferably meant oral cancer or cancer of the digestive tract. The following examples are provided to illustrate the invention and should in no way be construed as a limitation of the scope of the invention.
Claims (10)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1402031A FR3025722A1 (en) | 2014-09-11 | 2014-09-11 | ANTIOXIDIZING FOOD COMPOSITION IN THE FORM OF GEL |
| PCT/EP2015/001807 WO2016037698A1 (en) | 2014-09-11 | 2015-09-08 | Antioxidant food composition in gel form |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1402031A FR3025722A1 (en) | 2014-09-11 | 2014-09-11 | ANTIOXIDIZING FOOD COMPOSITION IN THE FORM OF GEL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR3025722A1 true FR3025722A1 (en) | 2016-03-18 |
Family
ID=51905183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1402031A Pending FR3025722A1 (en) | 2014-09-11 | 2014-09-11 | ANTIOXIDIZING FOOD COMPOSITION IN THE FORM OF GEL |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR3025722A1 (en) |
| WO (1) | WO2016037698A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201700048596A1 (en) * | 2017-05-05 | 2018-11-05 | Gabriele Bilancini | Composition based on turmeric extracts |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090087501A1 (en) * | 2007-10-01 | 2009-04-02 | Colgate-Palmolive Company | Oral Compositions Containing Botanical Extracts |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103734344A (en) * | 2013-12-19 | 2014-04-23 | 芜湖中路实业有限责任公司 | Healthcare garlic soybean milk and preparation method thereof |
-
2014
- 2014-09-11 FR FR1402031A patent/FR3025722A1/en active Pending
-
2015
- 2015-09-08 WO PCT/EP2015/001807 patent/WO2016037698A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090087501A1 (en) * | 2007-10-01 | 2009-04-02 | Colgate-Palmolive Company | Oral Compositions Containing Botanical Extracts |
Non-Patent Citations (2)
| Title |
|---|
| SANJAY KUMAR ET AL: "Therapeutic Plants of Ayurveda; A Review on Anticancer", PHARMACOGNOSY JOURNAL, vol. 3, no. 23, 1 July 2011 (2011-07-01), pages 1 - 11, XP055188892, ISSN: 0975-3575, DOI: 10.5530/pj.2011.23.1 * |
| YOSHIMI NIWANO ET AL: "Extensive screening for herbal extracts with potent antioxidant properties", JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, vol. 48, no. 1, 1 January 2010 (2010-01-01), pages 78 - 84, XP055188875, ISSN: 0912-0009, DOI: 10.3164/jcbn.11-013FR * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016037698A1 (en) | 2016-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Almeida et al. | Properties and applications of Morinda citrifolia (noni): A review | |
| Dhyani et al. | A review on nutritional value, functional properties and pharmacological application of perilla (Perilla frutescens L.) | |
| Mirzaei-Aghsaghali | Importance of medical herbs in animal feeding: A review | |
| Ajuwon et al. | Rooibos (Aspalathus linearis) and its major flavonoids—Potential against oxidative stress-induced conditions | |
| KR101861796B1 (en) | An antioxidant composition comprising platycodon grandiflorum extract | |
| Qiblawi et al. | Chemopreventive effect of cardamom (Elettaria cardamomum L.) against benzo (α) pyrene-induced forestomach papillomagenesis in swiss albino mice | |
| JP2006212021A (en) | Food composition | |
| Chanda et al. | Polyphenols and flavonoids of twelve Indian medicinal plants | |
| Hossain et al. | Antioxidative and anti-α-amylase activities of four wild plants consumed by pastoral nomads in Egypt | |
| ES2732247T3 (en) | Olive extract containing desramnosilacteósido | |
| FR2899768A1 (en) | Food supplement, useful as antioxidant, to improve the organ response or prevent the oxidative stress and to reduce aging, comprises gamma-tocopherol, flavonoids, carnosic acid and carnosol | |
| KR20170113809A (en) | beverage composition for protecting liver | |
| FR3025722A1 (en) | ANTIOXIDIZING FOOD COMPOSITION IN THE FORM OF GEL | |
| EP3405207B1 (en) | Detoxifying composition for oral administration and method for preparing same | |
| Deuschle et al. | Phytochemical screening and antioxidant activity of Origanum Majorana against oxidative stress biomarkers | |
| Omoregie et al. | In vitro antioxidant activity and the effect of methanolic extracts of some local plants on nutritionally stressed rats | |
| KR101878412B1 (en) | Traditional health tea using onion skin and natural materials and its manufacturing method | |
| KR101327645B1 (en) | Composition for antioxidative defenses system and muscle fatigue recovery comprising Angelica keiskei extract and Eisenia bicyclis extract as active ingredients | |
| Bajaj et al. | A review on antioxidant activity of coffee and its additives | |
| Atanassova et al. | Studies on nutritional facts of spring herbs collected from Bulgarian market | |
| Yang et al. | Green sweet potato leaves increase Nrf2-mediated antioxidant activity and facilitate benzo [a] pyrene metabolism in the liver by increasing phase II detoxifying enzyme activities in rats | |
| KR20110037020A (en) | The anti-diabetes composition containing silkworm culturing product and medicinal herbs | |
| Lim | Lepidium meyenii | |
| FR3017029A1 (en) | ACTIVE NUTRITIONAL PRINCIPLE OBTAINED FROM ANGUSTIFOLIUM VACCINE, COMPOSITION CONTAINING THE SAME AND USE THEREOF | |
| Mandalari et al. | Pistachio Nuts (Pistacia vera L.): Production, Nutrients, Bioactives and Novel Health Effects. Plants 2022, 11, 18 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20160318 |
|
| TP | Transmission of property |
Owner name: OTX SOLUTIONS, LU Effective date: 20160513 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |